,address1,address2,city,state,zip,country,phone,fax,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,lastSplitFactor,lastSplitDate,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,recommendationMean,recommendationKey,totalCash,totalCashPerShare,totalDebt,quickRatio,currentRatio,returnOnAssets,returnOnEquity,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,3960 Howard Hughes Parkway,Suite 500,Las Vegas,NV,89169,United States,917 595 2850,917 595 2851,https://pharmacyte.com,Biotechnology,Healthcare,"PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.",2,"{'maxAge': 1, 'name': 'Mr. Joshua N. Silverman', 'age': 52, 'title': 'Interim CEO, Interim Pres & Interim Chairman', 'yearBorn': 1970, 'fiscalYear': 2023, 'totalPay': 197917, 'exercisedValue': 0, 'unexercisedValue': 0}",1703980800,86400,4,2.61,2.61,2.46,2.61,2.61,2.61,2.46,2.61,0.0,-0.013485,-6.5789475,13842,13842,23551,17300,17300,2.49,2.5,800,800,21945250,2.3,3.23,2.588018,2.8651385,0.0,0.0,USD,-45129092,0.0,7162930,8778100,50126,48606,1690761600,1693440000,0.0057,0.09498999,0.20517,2.56,0.0126,4.328,0.577634,1682812800,1714435200,1682812800,-4315993,-0.23,-0.38,1:1500,1626048000,NCM,EQUITY,PMCB,PMCB,"PharmaCyte  Biotech, Inc.","PharmaCyte Biotech, Inc.",1357137000,America/New_York,EDT,-14400000,2.5,3.0,hold,68039936,7.751,0,115.994,116.178,-0.04923,-0.05308,-3518298,-3793731,0.0,0.0,0.0,USD,
1,3960 Howard Hughes Parkway,Suite 500,Las Vegas,NV,89169,United States,917 595 2850,917 595 2851,https://pharmacyte.com,Biotechnology,Healthcare,"PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.",2,"{'maxAge': 1, 'name': 'Mr. Carlos A. Trujillo CPA, CPA', 'age': 64, 'title': 'Chief Financial Officer', 'yearBorn': 1958, 'fiscalYear': 2023, 'totalPay': 380000, 'exercisedValue': 0, 'unexercisedValue': 840}",1703980800,86400,4,2.61,2.61,2.46,2.61,2.61,2.61,2.46,2.61,0.0,-0.013485,-6.5789475,13842,13842,23551,17300,17300,2.49,2.5,800,800,21945250,2.3,3.23,2.588018,2.8651385,0.0,0.0,USD,-45129092,0.0,7162930,8778100,50126,48606,1690761600,1693440000,0.0057,0.09498999,0.20517,2.56,0.0126,4.328,0.577634,1682812800,1714435200,1682812800,-4315993,-0.23,-0.38,1:1500,1626048000,NCM,EQUITY,PMCB,PMCB,"PharmaCyte  Biotech, Inc.","PharmaCyte Biotech, Inc.",1357137000,America/New_York,EDT,-14400000,2.5,3.0,hold,68039936,7.751,0,115.994,116.178,-0.04923,-0.05308,-3518298,-3793731,0.0,0.0,0.0,USD,
2,3960 Howard Hughes Parkway,Suite 500,Las Vegas,NV,89169,United States,917 595 2850,917 595 2851,https://pharmacyte.com,Biotechnology,Healthcare,"PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.",2,"{'maxAge': 1, 'name': 'Dr. Jose L. Iglesias M.D.', 'age': 65, 'title': 'Consulting Chief Medical Officer', 'yearBorn': 1957, 'exercisedValue': 0, 'unexercisedValue': 0}",1703980800,86400,4,2.61,2.61,2.46,2.61,2.61,2.61,2.46,2.61,0.0,-0.013485,-6.5789475,13842,13842,23551,17300,17300,2.49,2.5,800,800,21945250,2.3,3.23,2.588018,2.8651385,0.0,0.0,USD,-45129092,0.0,7162930,8778100,50126,48606,1690761600,1693440000,0.0057,0.09498999,0.20517,2.56,0.0126,4.328,0.577634,1682812800,1714435200,1682812800,-4315993,-0.23,-0.38,1:1500,1626048000,NCM,EQUITY,PMCB,PMCB,"PharmaCyte  Biotech, Inc.","PharmaCyte Biotech, Inc.",1357137000,America/New_York,EDT,-14400000,2.5,3.0,hold,68039936,7.751,0,115.994,116.178,-0.04923,-0.05308,-3518298,-3793731,0.0,0.0,0.0,USD,
3,3960 Howard Hughes Parkway,Suite 500,Las Vegas,NV,89169,United States,917 595 2850,917 595 2851,https://pharmacyte.com,Biotechnology,Healthcare,"PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.",2,"{'maxAge': 1, 'name': 'Dr. Hans-Peter  Hammes', 'title': 'Member of Medical & Scientific Advisory Board and Consultant', 'exercisedValue': 0, 'unexercisedValue': 0}",1703980800,86400,4,2.61,2.61,2.46,2.61,2.61,2.61,2.46,2.61,0.0,-0.013485,-6.5789475,13842,13842,23551,17300,17300,2.49,2.5,800,800,21945250,2.3,3.23,2.588018,2.8651385,0.0,0.0,USD,-45129092,0.0,7162930,8778100,50126,48606,1690761600,1693440000,0.0057,0.09498999,0.20517,2.56,0.0126,4.328,0.577634,1682812800,1714435200,1682812800,-4315993,-0.23,-0.38,1:1500,1626048000,NCM,EQUITY,PMCB,PMCB,"PharmaCyte  Biotech, Inc.","PharmaCyte Biotech, Inc.",1357137000,America/New_York,EDT,-14400000,2.5,3.0,hold,68039936,7.751,0,115.994,116.178,-0.04923,-0.05308,-3518298,-3793731,0.0,0.0,0.0,USD,
